Details of the Drug

General Information of Drug (ID: DMYNIG5)

• Drug Name: WS-070117

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Investigative	[1]

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 485.4
  Logarithm of the Partition Coefficient (xlogp); 1.1
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 12
• Chemical Identifiers:
  Formula: C22H23N5O8
  IUPAC Name: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-[6-(3-hydroxyanilino)purin-9-yl]oxolan-2-yl]methyl acetate
  Canonical SMILES: CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NC4=CC(=CC=C4)O)OC(=O)C)OC(=O)C
  InChI: InChI=1S/C22H23N5O8/c1-11(28)32-8-16-18(33-12(2)29)19(34-13(3)30)22(35-16)27-10-25-17-20(23-9-24-21(17)27)26-14-5-4-6-15(31)7-14/h4-7,9-10,16,18-19,22,31H,8H2,1-3H3,(H,23,24,26)/t16-,18-,19-,22-/m1/s1
  InChIKey: IUDLPZTURGVXEA-WGQQHEPDSA-N
• Cross-matching ID:
  PubChem CID: 45377904
  TTD ID: D0OH9B

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lipoprotein lipase (LPL)	TTOF3WZ	LIPL_HUMAN	Modulator	[1]

References

• [1] Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.